Corbus Pharmaceuticals Holding (CRBP) — Cash Flow-to-Debt Ratio
Corbus Pharmaceuticals Holding (CRBP) has a Cash Flow-to-Debt Ratio of -1.20x as of June 2026, meaning its operating cash flow of $-29.63 Million could theoretically repay -1% of its total liabilities ($24.75 Million) in one year. See financial flexibility index of Corbus Pharmaceuticals Holding to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Corbus Pharmaceuticals Holding Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Corbus Pharmaceuticals Holding across 14 annual periods. For the full cash flow conversion analysis, see CRBP cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Corbus Pharmaceuticals Holding (2012–2025)
Year-by-year debt coverage analysis for Corbus Pharmaceuticals Holding. Check Corbus Pharmaceuticals Holding cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.12x | $-64.49 Million | $20.69 Million | ▼ -0.3% |
| 2024 | -3.11x | $-41.79 Million | $13.45 Million | ▲ +99.7% |
| 2023 | -1026.25x | $-36.10 Billion | $35.18 Million | ▼ -90983.3% |
| 2022 | -1.13x | $-37.54 Million | $33.32 Million | ▲ +9.7% |
| 2021 | -1.25x | $-48.18 Million | $38.62 Million | ▲ +28.6% |
| 2020 | -1.75x | $-99.69 Million | $57.02 Million | ▼ -64.4% |
| 2019 | -1.06x | $-45.72 Million | $42.98 Million | ▲ +31.1% |
| 2018 | -1.54x | $-30.07 Million | $19.47 Million | ▲ +48.9% |
| 2017 | -3.02x | $-27.80 Million | $9.19 Million | ▼ -99.8% |
| 2016 | -1.51x | $-13.57 Million | $8.97 Million | ▼ -26.7% |
| 2015 | -1.19x | $-4.65 Million | $3.89 Million | ▲ +62.7% |
| 2014 | -3.20x | $-2.36 Million | $738.04K | ▼ -1722.3% |
| 2013 | -0.18x | $-366.71K | $2.09 Million | ▲ +83.0% |
| 2012 | -1.04x | $-769.73 | $743.36 | — |